British Biotech out-licenses lexipafant

British Biotech (LSE:BBG; BBIOY) signed an agreement giving DevCo (Guildford, U.K.) exclusive rights to develop, manufacture and sell lexipafant for the treatment of human diseases outside of oncology and ophthalmology. DevCo plans to develop the compound as a prophylaxis to neurological and renal complications for patients undergoing heart surgery. BBG will supply DevCo with technical information on lexipafant and reserves of compound for development. DevCo will cover all the development costs and will pay BBG royalties. ...